HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief

This article was originally published in The Rose Sheet

Executive Summary

FDA pushes back deadlines for compliance with its final rule for sunscreen labeling and effectiveness testing, giving manufacturers an additional six months for products with annual sales of at least $25,000. More news in brief.

You may also be interested in...

Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012

“The Rose Sheet” offers an overview of the year in cosmetics, analyzing 2012’s biggest news and the publication’s most-read stories. Highlights include a proposal in Obama’s 2013 budget request to institute cosmetics user fees, the rash of late-year warning letters and regulatory developments in California.

PCPC’s “Skin Smart” Videos Promote Sunscreen Importance, Daily Use

Dermatologists discuss the benefits and science of sunscreen formulas, emphasize daily use and address sunscreen truths and myths in the first episode of the Personal Care Products Council’s “Skin Smart” video series.

Merck Settles Class Suit Targeting Coppertone Claims, Denies Wrongdoing

Merck agrees to pay a maximum of $10 million to consumers to settle class-action litigation. Firm’s compliance with sunscreen labeling and claims requirements that will become law in December under an FDA final rule satisfies plaintiffs, who took issue with past Coppertone claims that allegedly overstated products’ sun-protective benefits. The settlement in federal court resolves separate litigation against Coppertone filed in California state court.

Related Content

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts